A Sit Down With Cancer

Slideshow

A doctor sits down with Cancer to gauge its feelings towards new immunotherapy agents, lower smoking rates, and the US obesity epidemic.

As we bid farewell to last year, let us note that several exciting advances in the treatment of cancer were approved in 2017. New immunotherapy agents with high response rates against recalcitrant tumors led some of us optimistic types to believe that for the first time we might have unearthed the secret to victory. I tried to remain cool and collected while daydreaming about the day when this vile disease is eradicated, but my enthusiasm got the best of me and, like a cheeky reporter, I went so far as to schedule an interview with Cancer, in order to gauge how sanguine it feels about the future. Like Porfiry Petrovitch, the magistrate in Crime and Punishment who questions the murderer Raskolnikov, I sat down with Cancer, ready to interrogate it under the klieg lights. Here are some excerpts from our conversation.Caption/concept by Craig R. Hildreth, MDArtwork by Jon Carter, cartertoons.com

Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
A panel of 4 experts on lung cancer
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.